INTRODUCTION

In 1919, long before the era of antibiotics and intensive care, Herrick stated with respect to meningococcal infections, “no other infection so quickly slays” (217). More than 80 years later, this still holds true. Because healthy young children are primarily the victims of this disease, its incidence continues to increase, and the mortality is still 10% (204, 346, 348, 376); social, medical and scientific vigilance is still required (126).

*N. meningitidis* is an exclusively human, gram-negative, bean-shaped pathogenic diplococcus that, similar to other gram-negative bacteria, is surrounded by an outer membrane composed of lipids, outer membrane proteins (OMPs), and lipopolysaccharides. Moreover, pathogenic meningococci are enveloped by a polysaccharide capsule attached to this outer membrane.

Meningococci reveal more genetic diversity than most other pathogenic human bacteria. This is explained partly by hori-

---

* Corresponding author. Mailing address: Department of Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands, and Department of Pediatrics, Ullevål University Hospital, Oslo, Norway

---

CLINICAL MICROBIOLOGY REVIEWS, Jan. 2000, p. 144–166

© 2000, American Society for Microbiology. All Rights Reserved.
trophoresis, which identifies naturally occurring allelic variation in multiple chromosomal housekeeping genes, a better insight into the epidemiology and clonal expansion of disease-causing *N. meningitidis* can be gained. Other techniques used to this end are DNA fingerprinting and PCR (36, 148, 424, 541).

### EPIDEMIOLOGICAL TRENDS

Meningococcal disease occurs worldwide as endemic infections (2, 80, 242, 346, 383, 421). Strains of serogroups B and C cause the majority of infections in industrialized countries. Strains of serogroups A and, to a lesser extent, C dominate in third-world countries (2, 80, 242, 315, 346, 383, 421). The incidence of meningococcal disease during the last 30 years varies from 1–3/100,000 in most industrialized nations to 10–25/100,000 in some third-world countries. These different attack rates reflect the different pathogenic properties of *N. meningitidis* strains and different socioeconomic, environmental, and climatological conditions.

Sub-Saharan Africa has a special epidemiological pattern. This region, designated the meningitis belt, was first described by Lapeyssonnie in 1963 and comprised 10 countries i.e., Burkina Faso, Ghana, Togo, Benin, Niger, Nigeria, Chad, Cameroon, Central African Republic, and The Sudan (271). Later, Ethiopia, Mali, Guinea, Senegal, and the Gambia were added, to form what is presently denoted the expanded meningitis belt (183, 383). In this region, meningococcal disease caused by serogroup A occurs in yearly recurrent waves. The disease attack rate rises at the end of the dry season and declines rapidly after the beginning of the rainy season (2, 271, 315, 346, 383, 421). During epidemic peaks, the disease incidence may approach 1,000/100,000 inhabitants (383). Initially, a cyclic pattern with epidemics every 8 to 12 years was reported, but this has not been confirmed in later studies for most of the countries (271, 315, 383).

Since the end of the 1960s, widespread epidemics due to genetically closely related strains of *N. meningitidis* belonging to seven clonal complexes have occurred (80). The largest outbreaks, which originated in northern China and spread to the south and later globally, were caused by two clones of serogroup A (subgroups I and III) (2, 80, 553). The subgroup III clone spread to the Indian subcontinent in 1983 to 1987. In 1987, this clone reached the Middle East and caused a massive epidemic among pilgrims during the Haj in Mecca (2, 80, 383, 421). From here the organism was transported with the Hajis (318), causing epidemics in 1988 in The Sudan and Chad and in the following years in Ethiopia, Kenya, and Uganda (315).

In the 1990s, the epidemic moved to countries south of the traditional meningitis belt, reaching Nigeria and South Africa in 1996 (305). In that year, more than 150,000 cases and at least 16,000 deaths were reported in Africa (2, 80, 189). Interestingly, transfer of strains from the same clonal complex by Hajis to the United States and Europe did not elicit epidemics in these parts of the world (316, 318).

In most industrialized countries, serogroup B strains have prevailed the last 30 years. Most of these strains belong to a few clonal complexes, identified as ET-5, lineage III, cluster A4, and ET-37 (80). In northwestern Europe (Norway, Iceland, England, and The Netherlands), hyperendemic infections with an attack rate of 4 to 50/100,000 have prevailed since the mid-1970s (2, 80, 242, 315, 346, 383, 414, 421). This persistent relatively high attack rate is caused mainly by serogroup B strains belonging to the ET-5 complex or lineage III. This strain circulates slowly through the population with a low transmissibility but a high degree of virulence (2, 80, 242, 346, 383, 415, 421).

Group B isolates with ET-5 characteristics were discovered in China in 1974 and in China, Japan, Thailand, Spain, Cuba, Chile, and Brazil in the 1980s. During the 1990s, ET-5 strains have also spread to North Africa, Israel, and Australia (80). In the United States, cases were reported among Cuban immigrants, but in contrast to northwestern Europe, no large epidemics developed. However, in the 1990s an epidemic outbreak caused by the ET-5 clonal complex occurred in the U.S. Pacific Northwest (Oregon) (35). Although in a few cases capsular switching from serogroup B to C was observed, the genetic relatedness and the disproportionate number of cases among young adults demonstrated clearly the transition from an endemic to an epidemic situation (86, 347, 461).

At the same time as the ET-5 clonal complex spread around the world, strains belonging to another serogroup B clonal complex designated lineage III (ET-24 and ET-25) emerged in Europe. First discovered in the Netherlands in 1980, this clone became the most prevalent clone, consisting almost exclusively of B:4:P:1.4 strains by 1990 (415). Later, this organism spread to other European countries, including Finland, Norway, and Iceland, although only a few cases occurred in these countries (80). From the beginning of the 1990s, New Zealand experienced a sharp rise in cases caused by lineage III strains (302). In the second half of the 1990s, an increasing number of cases were observed in the United Kingdom, Belgium, and Chile (80, 503).

Strains belonging to the ET-37 clonal complex, which often express serogroup C capsule polysaccharide but also may express serogroup B, W-135, and Y, are found worldwide (80). An isolate belonging to this clonal complex was traced back to at least 1917. In the 1960s, ET-37 strains caused outbreaks among military personnel in the United States (80). In the 1970s, these strains probably spread to Brazil, causing large serogroup C epidemics (80). At the same time, ET-37 strains that expressed the serogroup B capsule were isolated in China, and in the late 1970s serogroup B ET-37 strains were recovered in South Africa (80). In other African countries, serogroup C as well as serogroups W135 and Y strains belonging to the ET-37 complex emerged. In the 1980s, most pathogenic serogroup C strains isolated in Europe and the United States belonged to this complex (80, 357).

When ET-37 variant strains designated ET-15 appeared at the end of the 1980s in North America, the disease attack rate increased (15, 234, 386). In addition, an increasing number of local outbreaks, such as school-based clusters or epidemics originating in a jail, occurred (465, 549). Nevertheless, 90% of the serogroup C cases in the United States are sporadic (378). In the 1990s, ET-15 strains caused outbreaks in Israel, the Czech Republic, Australia, and England (80). Recently, isolates belonging to the ET-15 complex with a serogroup B capsule were found in Canada (256).

In parts of the United States, serogroup Y strains belonging to the ET-508 and related clones emerged in the mid-1990s as an important cause of endemic case clusters. Approximately one-third of the cases in certain areas of the United States are due to this serogroup Y strain (375, 444). Serogroup C strains are responsible for another one-third of cases in the United States, with the remainder of cases being caused by serogroup B and uncommon serogroups (375). The relatively high incidence of serogroup Y cases in the United States is of particular interest since in Europe this serogroup is found almost exclusively in patients with terminal complement deficiencies (140).

Epidemiological studies by modern molecular methods have disclosed a complex picture of a few pathogenic meningococcal...
clones spreading worldwide. However, the mechanism by which potential pathogenic strains cause large-scale epidemics in some regions while other regions remain unaffected is largely unknown (318). It appears that the occurrence of invasive meningococcal disease is not determined solely by the introduction of a new virulent bacterial strain but also by other factors that enhance transmission and by the susceptibility of the population (444).

CONDITIONS FOR INVASIVE DISEASE

At least four conditions have to be met before invasive disease can occur (421). These conditions are (i) exposure to a pathogenic strain, (ii) colonization of the naso-oropharyngeal mucosa, (iii) passage through that mucosa, and (iv) survival of the meningococcus in the bloodstream. These processes are influenced by bacterial properties, climatological and social conditions, preceding or concomitant viral infections, and the immune status of the patient.

Exposure to Meningococci

The human naso-oropharyngeal mucosa is the only natural reservoir of N. meningitidis. Meningococci are transferred from one person to another by direct contact or via droplets for a distance up to 1 m (331). No exact figures are available, but it seems plausible that the survival of bacteria in these droplets is influenced by climatological conditions such as temperature and humidity. During periods of endemic infection, approximately 10% of the population harbors meningococci in the nose (77, 82, 83, 182). However, 9 of 10 strains isolated from carriers are considered nonpathogenic because they are not associated with the clones cultured from patients with invasive meningococcal disease (33). In three different cross-sectional studies in Norway and the United Kingdom, the carriage rate in children younger than 4 years was <3%. The carriage rate increases with age to a maximum of 24 to 37% at 15 to 24 years, and decreases to <10% at older ages (33, 77, 82, 83). Most adults and children harbor the nonpathogenic Neisseria lactamica (77, 173). The carriage rate of meningococci is higher in lower socioeconomic classes, probably because of crowding, and under conditions where people from different regions are brought together, as for military recruits, pilgrims, boarding-school students, or prisoners (175, 176, 318, 351, 418, 465).

Predicting disease from carriage rates during periods of endemic infection is impossible (S. Kellerman, K. McCombs, P. Pathela, C. Drenzek, A. Margolis, L. Gilbert, J. Bierschling, M. Ray, L. Cobb, W. Cheek, J. Koehler, O. Blake, N. Rosenstein, W. Baughman, M. Farley, and D. Stephens, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. L32, 1998). The transmission rate of virulent clones is higher, and invasive disease often occurs within the first week after acquisition (130, 300), whereas some persons may carry pathogenic meningococci for many months or years without becoming ill (72). Calculations in Norway suggest that during the endemic situation, acquisition of the pathogenic clones ET-5 and ET-37 induced illness in only 1% of persons harboring these clones (82).

Colonization of the Naso-Oropharyngeal Mucosa

Why certain strains colonize the naso-oropharyngeal mucosa and others do not is the subject of extensive research (310, 329, 364). Colonization takes place both at the exterior surface of the mucosal cell and intra- or subepithelially (446, 449). Damage to the nasopharyngeal ciliated epithelium may be the first step in colonization (379, 451). Physical damage by active or passive smoking increases the risk for carriage and invasive disease (144, 199, 442, 458), as do stressful events and preceding viral infections which either alter the integrity of the mucosal surface or influence local or systemic immunity (78, 199, 317, 380).

Pili are the major adhesins that contribute to the attachment to mucosal cells. These filamentous glycosylated protein appendages emanate from the bacterial surface, traverse the capillary polysaccharide, and bind to receptors on nasopharyngeal cells, i.e., the membrane cofactor protein or CD46 (251, 511). Binding to this receptor transduces a signal to the host cell (250).

After primary binding, further contact with the host cell is established via the class 5 OMPs, Opa and Opc. Opc binds to carcinoembryonic antigen CD66 receptors (513). Interaction with these receptors on phagocytic and endothelial cells mediates phagocytosis and cytokine production (310). Opc binds to heparan sulfate proteoglycan receptors (118). Binding to both types of receptors stimulates the engulfment of meningococci by epithelial cells and transcellular traversal (108). Interestingly, these processes are hindered by the presence of a capsule or sialylated LOS (450, 512), factors that are indispensable for survival of meningococci in the bloodstream (see "Survival of the meningococcus in the bloodstream" below).

During carriage and invasion, the expression of pili, class 5 OMPs, capsule, and LOS is highly variable and subject to phase switching (on/off) and antigenic variation (3, 119, 245, 329). These mechanisms can be used by the bacterium to circumvent host immunity (329, 364).

Invasion or Penetration of the Naso-Oropharyngeal Mucosa

Meningococci pass through the mucosal epithelium via phagocytic vacuoles as a result of endocytosis (306, 329, 381, 446, 448, 450). During invasion, several bacterial factors modulate the metabolism of the mucosal cell (510). As mentioned above, binding of pili and class 5 OMPs to their receptors transduces a signal to the host cell. PorB, a class 2/3 OMP, may translocate into target cell membranes and affect the maturation of phagosomes (401). IgA1 proteases are OMPs that inactive specific IgA1 (323, 514). By stimulation of the degradation of a membrane glycoprotein in endosomes and lysosomes, they also promote the survival of meningococci in epithelial cells (18).

Frequently, invasive disease is preceded by Mycoplasma pneumoniae or viral (influenza A virus) upper respiratory tract infections; it is assumed that this preceding infection promotes invasion (289, 317, 547). However, it should be noted that these epidemiological studies are prone to confounding bias, since respiratory infections increase mechanical transmission of meningococci by sneezing and coughing and since meningococci themselves may cause signs of upper airway infection (339; J. V. Pether, R. J. Scott, and P. Hancock, Letter, Lancet 344:1636, 1994).

Survival of the Meningococcus in the Bloodstream

Meningococci can survive and proliferate in the bloodstream by virtue of particular bacterial virulence factors or incompleteness of the host defense.

Members of the Neisseriaceae have developed a mechanism for acquiring iron from human transferrin by using transferrin binding proteins (353, 417). However, the most essential bacterial virulence factor for survival in the bloodstream is the polysaccharide capsule, which protects against complement-mediated bacteriolysis and phagocytosis by neutrophils, Kupffer cells, and spleen macrophages (260). In brief, sialic acid resi-
dues in the group B and C capsule and possibly LOS immunotype L3 decrease the serum bactericidal activity by enhancing the affinity of the alternative-pathway inhibitor factor H to C3b and thus inhibiting complement activation (112, 136, 137, 239, 245, 248, 260, 398, 515). In addition, some class I OMPs impede ingestion of the meningococcus by neutrophils via downregulation of the Fcγ receptor and the C1 and C3 receptor (34), and IgA1 proteases break IgA1 in the hinge region and liberate monomeric Fabα fragments, which can block the access for intact IgG or IgM (325).

Host defense after meningococcal invasion is determined by humoral and cellular responses belonging to the innate and adaptive immune systems. Specific antibodies provide full protective activity. However, because the production of antibodies takes at least 1 week after colonization, the initial defense is dependent primarily on elements of the innate response.

Cornerstones of the early innate defense are complement-mediated bacteriolysis and opsonophagocytosis. Early complement activation occurs via the mannose binding lectin and the alternative pathway. Some genetically determined variants of mannos binding lectin predispose to invasive disease (219). Alternative-pathway defects such as X-linked properdin deficiency may lead to overwhelming invasive disease (138, 435). Deficiency of one of the terminal complement factors increases the chance for invasive disease, mainly by uncommon serogroups, up to 6,000-fold (112, 139, 140, 397). However, due to the rarity of these deficiencies, only a few cases can be explained by these defects. In a Norwegian survey of 98 individuals who survived meningococcal disease, no patient with a complete deficiency was found, and a Dutch study of 29 children surviving fulminant shock revealed only 1 case (115, 223). Deficiency of protein C, a regulator involved in the coagulation, anticoagulation, and fibrinolytic systems, leads to extensive diffuse intravascular coagulation (DIC) and necrosis (138).

In normal individuals, the incidence of meningococcal disease is reciprocally related to the titer of specific antibodies, with the highest incidence occurring from 6 to 24 months of age, when maternal antibodies have disappeared (175, 176).

Throughout life, specific antibodies are induced by the continuously repeated and intermittent carriage of different meningococci and N. lactamica (175, 175, 176, 247). Certain enteric bacteria have a capsule that is structurally and immunologically identical to the capsular polysaccharide of meningococci. This is the case for Bacillus pumilus and serogroup A meningococci, and for Escherichia coli K1 and serogroup B strains (178, 253, 504). It has been suggested that these bacteria contribute to the defense against meningococci by the induction of cross-reacting antibodies (253, 504). On the other hand, it has been suggested that IgA antibodies, which do not activate complement, may adhere to important epitopes and block these epitopes for the bactericidal effects of complement-activating IgG and IgM antibodies (185, 186). The importance of blocking IgA antibodies is still being debated.

Although specific antibodies provide full protection against invasive disease, only a few cases have occurred in patients with hypogammaglobulinemia (216, 281; J. L. Bass, R. Nuss, K. A. Mehta, P. Morganelli, and L. Bennett, Letter, N. Engl. J. Med. 309:430, 1983). Interestingly, a genetic polymorphism of the Fcγ receptor [FcγRI(a/CD32)] that binds IgG2 poorly and leads to diminished opsonophagocytosis predisposes individuals to meningococcal disease (62).

The relevance of cellular immune defects is less well established. There is no proven relation between meningococcal disease and HLA phenotype (266). Splenectomy is a well-defined risk factor for overwhelming infections with encapsulated bacteria; however, invasive meningococcal disease is only rarely observed in splenectomized individuals (227, 294). Immunosuppressive drugs or autoimmune diseases such as lupus erythematosus are risk factors (292, 312). Human immunodeficiency virus seropositivity is not a defined risk factor (63, 334), although cases in human immunodeficiency virus-seropositive individuals have been reported (447).

In conclusion, growth of the meningococcus in the bloodstream can occur when intravascular killing is impaired, either because of special properties of the meningococcus itself or because of a naive or defective immune system of the host.

**CLINICAL PRESENTATION OF INVASIVE MENINGOCOCCAL DISEASE**

Once viable meningococci have reached the bloodstream, different disease manifestations can develop. In some patients, probably those with low degrees of bacteremia, meningococci are cleared spontaneously, leaving behind a so-called transient meningococcemia characterized by a short febrile flu-like episode (104, 162, 427, 459; S. P. Taubkin, Letter, Pediatr. Infect. Dis. J. 13:374). When the bacteremia is not cleared, clinically overt disease develops. In these cases, the ultimate clinical presentation is determined by bacterial properties such as endotoxin release and by host characteristics such as the host immune status (see “Survival of the Meningococcus in the Bloodstream” above) and possibly endotoxin responsiveness.

Endotoxin release is a strain-specific virulence factor. During growth and lysis of meningococci, endotoxin is released in the form of vesicular outer membrane structures (blebs) consisting of up to 50% of LOS, and OMPs, lipids, and capsular polysaccharides (117, 479). During invasive disease, these structures can be visualized in plasma or cerebrospinal fluid (CSF) by electron microscopy (48, 445). Strains isolated from patients with meningococcal septic shock liberate more endotoxin than do strains isolated from patients with chronic benign meningococcemia (368).

Endotoxin-induced cytokine production differs among individuals (64). This genetically determined trait is referred to as endotoxin responsiveness. Originally it was suggested that patients who develop overwhelming sepsis are highly endotoxin responsive, i.e., genetically inclined to produce larger amounts of proinflammatory cytokines such as tumor necrosis factor (TNF) (326, 533). Later studies suggested that a short-term TNF production and an increased production of the anti-inflammatory interleukin-10 (IL-10) correlate with a poor prognosis (531). However, this latter view conflicts with observational studies by Waage et al., who found a striking association between massively elevated levels of bioactive TNF in serum and death (517, 518). Since shock and high cytokine concentrations are encountered particularly in patients with low titers of bactericidal antibodies and high titers of capsular antigen or endotoxin, unimpeded and massive outgrowth of meningococci is probably much more important than the phenomenon of endotoxin responsiveness (54, 55, 57, 129, 194, 495, 535).

In nearly all patients who develop shock and in most patients with meningitis, the beginning of the bacteremic phase is marked by the onset of chills, acute fever, low-back pain, thigh pain, or generalized muscle aches (296). Within a few hours, fulminant meningococcal sepsis (FMS) may develop without signs of meningitis; this condition is characterized by high concentrations of endotoxin and cytokines in plasma (Fig. 1). Because one of the striking features of meningococci is their propensity to invade the meninges (217, 327, 329), patients with less marked bacterial proliferation in the bloodstream and less cytokinemia present after 18 to 36 h with meningitis. In these patients, blood cultures are often negative at time of
hospitalization. Due to the limited growth of bacteria in the bloodstream and the seeding of meningococci in the subarachnoid space, patients with meningitis have compartmentalized high concentrations of endotoxin and cytokines in the CSF (50, 495).

Based on the sequence of pathophysiological events, patients with invasive meningococcal disease can be classified into four groups (163): (i) patients with bacteremia without shock, (ii) patients with bacteremia with shock but no meningitis (i.e., FMS), (iii) patients with shock and meningitis, and (iv) patients with meningitis alone. This classification correlates with the duration of disease before hospitalization (Fig. 1); the site, severity, and pattern of mediator activation; and the prognosis. Classification of patients into one of these clinically easily recognizable groups is a great help for clinical decision-making, particularly for the installation of immediate and maximal intensive-care support (54, 55, 192, 193, 495, 498, 517; M. Van Deuren, J. van der Ven-Jongekrijg, and J. W. M. van der Meer, Proc. 3rd Int. Symp. Chemotactic Cytokines, abstr. P-28, 1992).

Incidentally, other compartmentalized metastatic infections, such as arthritis or pericarditis, can develop; the latter is caused mainly by serogroup C (38, 404, 529; T. W. Austin and K. R. Gurr, Letter, Clin. Infect. Dis. 20:473, 1995; D. S. Damary, D. A. Sherlock, and J. Crosall, Letter, J. Infect. Dis. 135:320–321, 1997). Cellulitis and endophthalmitis have been found occasionally (292, 338; T. Sleep and M. Graham, Letter, Br. J. Ophthalmol. 81:1016–1017, 1997). Primary pyogenic arthritis or pericarditis should not be confused with the reactive, immune complex-mediated arthritis or pericarditis, which is often combined with a rash and recrudescence of fever and occurs in 10 to 20% of the patients on days 4 to 7 during the convalescent phase of meningococcal disease (184). A small group of patients, probably less than 1% and consisting mainly of adults, can present with one or more episodes of spiking fever, arthralgia, or arthritis and a recurrent rash; this syndrome is designated chronic benign meningococcemia (360; R. F. Wynn, R. B. S. Laing, C. L. S. Leen, P. Stratham, and F. X. Emmanuel, Letter, Clin. Infect. Dis. 18:829–830, 1994).

How these patients tolerate the potentially lethal bacterium for several weeks in their bloodstream is not understood. In addition to these blood-borne infections, other meningococcal infections such as primary meningococcal conjunctivitis, pneumonia, sialadenitis, adenitis, or pelvic inflammatory disease have been reported (9, 20, 24, 164, 402; J. D. Cher, W. J. Maxwell, N. Frustujer, M. Marin, and L. D. Wiviott, Letter, Clin. Infect. Dis. 17:134–135, 1993). Meningococcal pneumonia occurs principally in immunocompromised or elderly patients (447). The diagnosis is easily overlooked because clinically there is nothing to differentiate it from pneumonia of other nosocomial causes (246), meningococci are easily missed in cultures of respiratory secretions, and the disease responds to standard antibiotic therapy (105). Meningococcal infections in the upper or lower airways, genitals, and anus differ clearly from invasive disease, since they develop without preceding bacteremia. However, vigilance is still needed since these infections may precede invasion and may cause secondary cases (246, 337, 395; G. Holdsworth, H. Jackson, and E. Kaczmarski, Letter, Lancet 348:1443, 1996).

**PATHOPHYSIOLOGY OF INVASIVE DISEASE**

**Pathophysiology of Fulminant Meningococcal Sepsis**

FMS is characterized by shock and DIC, two interrelated processes. Shock and DIC have common causal mechanisms and reinforce each other. For instance, microvascular thrombosis leads to hypoperfusion (i.e., shock) and shock induces endothelial damage and DIC. To quote Hardaway, “Shock is both cause and effect of DIC” (200).

**Pathophysiology of shock.** Shock is caused by capillary leakage, inappropriate vascular tone, intravascular microthrombi,
and myocardial dysfunction. The central activator that elicits these derangements is meningococcal endotoxin (6, 69, 212), and the severity of shock correlates with the degree of endotoxinemia (54, 55, 57, 495).

From the early onset of disease, meningococcal endotoxin activates zymogens belonging to the complement system, contact system, and kallikrein-bradykinin system. Since activation of these zymogens requires only proteolytic cleavage by a serine protease, the activated factors of these systems appear immediately. Similarly, neutrophils release elastase and other lysosomal proteinases instantaneously from their storage pools (88, 440). Endotoxin also induces the production, expression and release of mediators such as tissue factor (TF), tissue plasminogen activator (TPA), and the pro- and anti-inflammatory cytokines. Since these latter mediators are proteins that have to be synthesized, they appear approximately 1 to 2 h later than the activated zymogens and proteins released from storage pools (88). Nearly all these mediators can induce shock, either alone or in synergy.

In the early stage of invasive disease, complement is activated mainly by the alternative pathway and partly by the classical or mannose-binding lectin pathway (51, 55, 209). The degree of complement activation correlates with the severity of shock (55, 209, 224). Because complement activation takes place on blebs, no effective complement-mediated bacteriolysis occurs. The relative deficiency of the regulatory proteins C4 binding protein (C4bp) and C1 inhibitor (C1-INH), due to consumption and downregulated production, contributes to the unimpeded activation of complement via the classical pathway (209). The resulting increase of the anaphylatoxins C3a and C5a causes, in concert with bradykinin and the elastase-induced endothelial damage, vasodilatation and capillary leakage.

High cytokine concentrations correlate with the severity of shock. After the first observation in 1987 by Waage et al. that TNF levels in serum correlated with mortality (318), similar patterns were reported for other cytokines such as IL-1β, IL-6, IL-8, leukemia inhibitory factor, gamma interferon, granulocyte colony-stimulating factor, monocyte colony-stimulating factor, and granulocyte-monocyte colony-stimulating factor (168, 192, 263, 495, 498, 517, 526, 527; Van Deuren et al., Abstr. Proc. 3rd Int. Symp. Chemotactic Cytokines). Likewise, the levels of the anti-inflammatory cytokines IL-10, IL-12, and IL-1 receptor antagonist (IL-1Ra) and both TNF soluble receptors (TNF-FRs) are increased (113, 169, 210, 283, 489, 495, 496, 498). The exact role of these cytokines in the genesis of shock is difficult to define, since their activity is modulated by the simultaneous presence of soluble cytokine receptors. For instance, IL-6 activity is upregulated by the diminished levels of IL-6 soluble receptor (IL-6sR) in plasma (14, 154) while TNF activity is downregulated by the increased TNF-FRs levels (169).

Because the ratio of TNF to TNF-FR is higher in severe shock than in moderate disease, the original concept was that the proinflammatory cytokine activity outweighs the anti-inflammatory activity in severe shock (169). However, more recent studies underline the importance of proinflammatory cytokines in the initial defense against bacteria. The production of proinflammatory cytokines by peripheral blood cells is downregulated in the early stages of invasive disease (493, 496). Relatives of persons who died of their meningococcal infection produced less TNF and more anti-inflammatory IL-10 than did relatives of survivors (531). In addition, it was shown that the plasma of patients with shock inhibits the cytokine-inducing and procoagulatory activities of endotoxin (56, 206) and that patients with fatal sepsis of various etiologies have lower levels of TNF and higher levels of IL-10 (500). Together, these observations suggest that in severe shock, in spite of a strong proinflammatory state, anti-inflammatory responses that are regulatory in nature are highly upregulated.

Regardless of the clinical course, the increased concentrations in plasma of all cytokines and other mediators involved in the genesis of shock and DIC (see the next section) decline rapidly after the start of antibiotic therapy, suggesting an efficient clearing mechanism and downregulated production (158, 488, 493, 496, 517, 526, 527). Antibiotic-induced increases in the levels of endotoxin or cytokines have never been demonstrated in clinical studies (54, 158, 487, 517). In the Intensive Care Unit (ICU) of the University Hospital Nijmegen, we monitored the course of TNF and IL-1 from admission to recovery or death in 37 FMS patients; TNF and IL-1 concentrations increased after admission in only 1 patient (487). Since this patient was the only patient in the study who did not receive prompt antibiotic treatment because the diagnosis was missed initially, these data advocate strongly against postponement of antibiotic therapy.

The decrease in the level of endotoxin has a half-life of approximately 3 h (54, 494). The half-lives for TNF and IL-1 are 1 to 3 h and 2 h, respectively (158, 488, 517). The half-life for IL-6 is 2 to 6 h (154, 517; R. G. I. Westendorp, A. Brand, J. Haanen, V. W. M. van Hinsbergh, J. Thompson, R. van Furth, and E. A. Meinders, Letter, Am. J. Med. 92:577–578, 1992), similar to that of IL-8 and IL-10 (283; Van Deuren, et al., Abstr. Proc. 3rd Int. Symp. Chemotactic Cytokines). In contrast, the half-life of TNF-FRs is 3 to 5 days (489). IL-1Ra and plasminogen activator inhibitor 1 (PAI-1) levels may peak shortly after admission and decline afterward, with a half-life of approximately 6 to 12 h (52, 498). Interestingly, the complement system is the only mediator system that shows ongoing activation during the first 12 to 24 h after the initiation of antibiotic therapy (51, 55, 209), and it is tempting to hypothesize that the clinical deterioration that is sometimes observed after the start of therapy (the Jarisch-Herxheimer reaction) (30) is caused by this continuing activation of complement.

DIC and myocardial depression further aggravate the shock state (31, 45, 314). One of the typical features of FMS is that myocardial depression caused by endovascular thrombosis, vasculitis, and a circulating myocardial depressant factor (possibly TNF or IL-1) reaches its maximum within a few hours after admission (39, 202, 208, 268, 309). Echocardiography performed at this time shows an increased end-diastolic volume and decreased left-ventricular shortening fraction. The cardiodepressive state may last for 7 to 10 days. Involvement of the conductive system may cause life-threatening bradyarrhythmias (392, 426). Cardiac tamponade due to an immune-complex-mediated sterile pericarditis may lead to hemodynamic deterioration during the recovery phase of any invasive meningococcal infection (321, 356).

**Pathophysiology of DIC**

Skin hemorrhages are the hallmark of invasive meningococcal disease. Microscopically, these lesions are characterized by endothelial damage and hemorrhages around and microthrombi in small vessels, consistent with a generalized Sanarelli-Shwartzman reaction. The lesions are a reflection of the endotoxin- and cytokine-primed vasculitis that is mediated by the upregulation of adhesion molecules on endothelium and degranulating activated neutrophils (13, 220, 322, 439). Clinically, they are the visual manifestations of DIC and consumption coagulopathy. Although DIC is a generalized phenomenon affecting all organs, the adrenals are particularly vulnerable. Adrenal hemorrhages, diagnosed postmortem as Waterhouse-Friderichsen syndrome, may lead to...
transitory adrenal insufficiency (39, 43, 201, 522). It is of interest that the intracerebral vessels remain spared during FMS.

Most of our knowledge of sepsis-induced DIC originates from infusion experiments with endotoxin, TNF, or other cytokines such as IL-1 and IL-6 and in vitro experiments with monocytes or endothelial cells exposed to these compounds (287, 288, 412, 486). One of the initial procoagulant processes elicited was the expression of TF, the initial step in the activation of the extrinsic coagulation pathway (218) that ultimately results in thrombin formation. In these experimental studies, thrombin inactivation is impaired by the downregulation of thrombomodulin on endothelial cells. This downregulation also impairs protein C function, which results in less inactivation of FVa and FVIIa and reduced activation of fibrinolysis. In these infusion experiments, activation of fibrinolysis by TPA occurs only during the first 3 h; after this time the fibrinolysis subsides because of the increasing concentrations of PAI-1 (287, 288).

Although endotoxin is a well-known activator of Hageman factor (FXII) (320), the intrinsic coagulation pathway or contact system is not activated in the low-dosage endotoxin infusion models. However, in patients with septic shock or in baboons with lethal experimental bacteremia, FXII is clearly activated (252, 336, 359), whereas the levels of C1-INH and \( \alpha_{2} \)-macroglobulin, the natural inhibitors of FXIIa, are decreased (106, 107). FXII activation during sepsis has multiple effects. FXIIa is the initiating protease of the contact system and activator of fibrinolysis, as well as an activator of complement. FXIIa further induces the conversion of prekallikrein to kallikrein, the enzyme that cleaves high-molecular-weight kininogen into the potent vasodilator nonapeptide bradykinin. Both complement activation and bradykinin formation induce hypotension. In addition, FXIIa stimulates the release of elastase by neutrophils, which probably plays an important role in the genesis of acute respiratory distress syndrome (ARDS) (79, 124).

Contact activation has been demonstrated in meningococcal infections. In patients with severe FMS, low levels of prekallikrein (60) and high levels of the elastase-antiprotease complex that reflects neutrophilic activation by endotoxin, TNF, FXIIa, or complement (53, 440) are found.

The significance of contact activation in lethal-sepsis models is demonstrated by the inhibition of FXIIa with monoclonal antibodies. FXIIa inhibition reverses hypotension and attenuates complement and elastase release but does not inhibit DIC (238, 358). However, in view of the myriad interactions between the various mediator networks, the close relationship between shock and DIC, and the fact that activation of the intrinsic coagulation pathway in FMS is well established (543), further study is needed to elucidate the role of FXII activation in the genesis of DIC in patients with FMS is warranted.

In meningococcal infections, severe DIC is associated with a very poor prognosis (211, 507). Østergard and Flagstad showed that an increased activity of TF on monocytes is associated with a high fatality rate (341). Other poor prognostic signs are a low concentration of FVII, FX, FV, FVIII, and fibrinogen in plasma, reflecting severe consumption-coagulopathy, and increased fibrinopeptide A levels, mirroring fibrin formation (58, 101, 141, 170, 272, 307). Also, low concentrations of the anticoagulant factors antithrombin III (AT-III), protein C, and protein S are associated with a poor prognosis (58, 142, 272, 278, 365; D. R. Powars, Z. R. Rogers, M. J. Patch, W. G. McGehee, and R. B. Francis, Jr., Letter, N. Engl. J. Med. 317:571–572, 1987). Similarly, low plasminogen levels in the very early stage and high PAI-1 concentrations, showing inhibition of fibrinolysis, are associated with a severe course of meningococcal septic shock, with respect to the time of hospital admission (continuous line) or ICU admission (dotted line).

**Outcome of Fulminant Meningococcal Sepsis**

The mortality rate of FMS is high and varies from 20 to 80% in different studies. This wide range can be explained partly by selection bias. Tertiary-care centers see more severely ill patients but may document better survival rates because a portion of the patients who die will do so before arrival at the ICU (Fig. 2). Variation in the reported mortality rates can be explained further by the diversity in the natural course of the disease and quality of medical treatment in the hours before arrival at the ICU. Finally, the difference can be explained by different disease definitions. Clinical studies include mainly patients with well-defined shock criteria, whereas many epidemiological studies define sepsis simply by the presence of a purpuric rash or positive blood culture. Clearly, unequivocal definitions are needed for reliable comparison of patients, therapies, and outcomes (H. T. Sorensen, F. H. Steffersen, G. L. Schonheyder, G. L. Nielsen, and J. Olsen, Letter, Br. Med. J. 316:1016–1017, 1998; M. J. Tarlow and A. M. Geddes, Letter, Lancet 340:1481, 1992).

Clinical deterioration is overwhelming, and approximately half of the patients who die will do so within 24 h after the first symptoms occur. As estimated from 24 patients who died in the ICU of the Nijmegen University Hospital (Fig. 2) and data reported in the literature (66, 133, 290, 299, 307, 309, 333), one-third of the patients with fatal disease die within 6 h after hospital admission and one-third die between 6 and 18 h. Death at a later stage is still determined by the course in the early hours, as shown by the fact that the principal cause of death after 24 h is withdrawal of treatment because of poor neurological prognosis after prolonged cerebral hypoperfusion in the early hours (313).

Recovery may be complicated by hemorrhages, ARDS, anuria, and multiple-organ failure. In some cases ARDS develops within a few hours after admission (537). Skin and limb necrosis requiring amputation or plastic surgery is seen in 10 to 20% of patients. Of the 55 survivors of FMS in the ICU of the
Between sepsis and meningitis is that in meningitis the inflammation clinically and histopathologically. The major difference is that the clearance of endotoxin and/or the regulation of the inflammatory process is different from that observed in sepsis. The cytokine response in meningococcal meningitis differs from that in blood during FMS. For instance, the ratio of TNF in CSF to TNF in blood during FMS is much higher in meningococcal meningitis than in sepsis. This difference can be explained by a different kinetic behavior of these cytokines, a different cellular source, or a different interplay between the immune response in the blood and the immune response in the meninges. The evolving endotoxin liberation and cytokine activation in the meninges are the result of the interaction between the immune system and the microorganisms. The early stages of meningococcal meningitis resemble that of sepsis, with a high rate of mortality and sequelae caused by endovascular inflammation and thrombosis. Meningococcal meningitis has a relatively low rate of mortality and neurological sequelae compared to other types of bacterial meningitis.

Pathophysiology of Meningococcal Meningitis

A great deal of our knowledge of the pathophysiology of bacterial meningitis is based on experiments in which bacteria are inoculated intracisternally (372, 480). Consequently, these models do not incorporate the immunological and endocrinological effects of a preceding bacteremia. The relatively rare studies that use an intranasal bacterial challenge mimic the human situation more closely (408).

The mechanisms behind the propensity of meningococci to invade the meninges and their passage across the blood-brain barrier are poorly understood (327, 329). Once in the subarachnoid space, where the principal humoral and cellular host defense mechanisms are absent (432, 555), meningococci proliferate uncontrollably (57). The evolving endotoxin liberation elicits compartmentalized (i.e., confined to the subarachnoid space) activation of proinflammatory cytokines such as TNF, IL-1, IL-6, IL-8, nitric oxide, monococyte colony-stimulating factor, and platelet-activating factor and anti-inflammatory cytokines such as IL-1Ra, IL-10, IL-12, TNFSR-p55, TNFSR-p75, and IL-1sRII type II (12, 57, 19, 264, 295, 429, 498, 502, 517, 519–521). Among these, TNF and IL-1 enhance the permeability of the blood-brain barrier and promote the influx of neutrophils by upregulation of adherence molecules (258, 374, 377, 428). The subsequent release of neutrophil products contributes to the development of clinically overt meningitis.

Antibiotics do not halt the meningeal inflammatory process immediately (11, 467, 469). Some studies show even a transient worsening of the inflammation after antibiotic administration, possibly due to the enhancement of endotoxin release (153, 324). This finding contrasts with studies of sepsis, where antibiotic-induced endotoxin release has never been observed (see “Pathophysiology of shock,” above, and “Antibiotic treatment” below). A possible explanation for this discrepancy is that the clearance of endotoxin and/or the regulation of the production of cytokines in the CSF differs from that in the blood compartment.

Analogous to the high concentrations of endotoxin, TNF, IL-1, and IL-6 in the plasma of patients with FMS, the concentration of these mediators in CSF of patients with meningitis is increased. However, cytokine activation in CSF is not a mere copy of that in blood during FMS. For instance, the ratio in CSF of TNFSR-p75 to TNFSR-p55 and the pattern of IL-1sRII in patients with meningococcal meningitis differs from that in plasma of patients with FMS (495, 498). This dissimilarity can be explained by a different kinetic behavior of these mediators, a different cellular source, or a different interplay with other mediator systems because zymogens, the starting players in the immune response in the blood compartment, are absent in native CSF.

The differences between FMS and meningitis are also evident clinically and histopathologically. The major difference between sepsis and meningitis is that in meningitis the inflammatory response is localized in an extravascular compartment devoid of zymogens belonging to the complement and coagulation systems. While meningococcal sepsis is the most devastating form of sepsis, with a high rate of mortality and sequelae caused by endovascular inflammation and thrombosis, meningococcal meningitis has a relatively low rate of mortality and neurological sequelae compared to other types of bacterial meningitis (21, 172, 419).

Outcome of Meningococcal Meningitis

Since the skull cannot expand, cerebral edema will result in increased intracranial pressure and impeded cerebral perfusion (16). Sometimes fatal brain stem herniation occurs. The 1 to 5% mortality rate associated with meningococcal meningitis is caused almost exclusively by this nearly intractable rapidly fatal complication (335; W. T. Conner and J. A. Minnilly, Letter, Lancet ii:967–969, 1980; T. Stephenson, Letter, Br. Med. J. 316:1015, 1998). In most of these cases, autopsy shows not only meningitis but also encephalitis in the regions adjacent to the meninges. In the 58 patients with meningococcal meningitis without shock, referred from 1984 to 1998 to the ICU of the University Hospital Nijmegen, brain stem comion occurred in five patients: three times before arrival at the emergency room and twice within 1 h before arrival at the ICU.

Reportedly, 8 to 20% of survivors suffer from neurological sequelae, varying from sensorineural deafness, mental retardation, spasticity, and/or seizures to concentration disturbances (21, 123, 131, 135, 363, 410). The incidence of neurological sequelae after meningococcal meningitis is lower than after pneumococcal meningitis (21), perhaps because meningococcal meningitis the subarachnoidal inflammation is extinguished faster (393). Cerebral abscesses do not occur after meningococcal meningitis.

Diagnosis and Recognition of Patients at Risk

Acute meningococcal disease, in particular FMS, can be fatal within a few hours. Therefore, early diagnosis and immediate recognition of (imminent) deterioration is pivotal.

Early diagnosis of meningococemia is extremely difficult and requires a high degree of suspicion (179, 180, 388). Typically, a completely healthy child complains of myalgia of sudden onset, chills, and fever (296). After 4 to 6 h, there may be a transient clinical improvement that conceals the ongoing deterioration. At this early stage, symptoms and signs are absent or confusing (97, 524). The initial skin manifestations resemble a viral rash (303, 388, 478; P. Baxter and B. Priestly, Letter, Lancet i:1166–1167, 1988); the neck is supple and ex-
or hemorrhagic skin lesions become apparent only 12 to 18 h after first disease symptoms, and in 20% of the patients these lesions never develop (49, 400, 477). When a patient presents with fever, headache, photophobia, irritability, vomiting, loss of consciousness, neck stiffness, and skin lesions, the diagnosis will not be missed. However, when focal neurology or behavioral disturbances dominate and skin lesions are absent, the diagnosis can still be overlooked (19).

Prompt bacteriological diagnosis in patients with FMS is possible with a Gram stain of a skin lesion biopsy specimen, buffy coat, or CSF (349, 499). In patients with meningococcal meningitis, skin lesions seldom reveal meningococci and only CSF samples are positive (499). Cultures become positive after 12 to 24 h. Prior antibiotic therapy jeopardizes the recovery of bacteria from cultures of blood and CSF but not from skin biopsy specimens (499). Other methods not affected by prior antibiotic administration are antigen detection or PCR on meningococcal DNA in blood or CSF (40, 41, 81, 332, 484).

Early diagnosis of FMS and recognition of patients at risk are crucial for the timely start of life-saving antibiotic and antishock therapy. In 1966, Stiehm and Damrosch published the first prognostic scoring system for the recognition of patients at risk (454). Meanwhile, multiple scoring systems have been published, all based on quickly available clinical and laboratory parameters (5, 8, 23, 26, 42, 116, 133, 149, 156, 160, 163, 170, 193, 211, 249, 262, 274–277, 293, 333, 340, 473, 475, 483, 507, 539; F. Leclerc, V. Hue, A. Martinot, and F. Delpeoule, Letter, Am. J. Dis. Child. 145:1090–1091, 1991; J. Sinclair, C. H. Skeoch, and D. Hallworth, Letter, Lancet ii:38, 1987). In summary, indicators of FMS and a poor prognosis are the extremes of age; a short period between onset of disease and admission; the absence of meningitis; progressive or widespread skin lesions; shock as shown by a slow capillary refill, cold acra, hypotension, or metabolic acidosis; a moderately elevated or normal C-reactive protein concentration in serum; the absence of leukocytosis; and the presence of thrombocytopenia, DIC, and hypofibrinogenemia. As discussed above (see “Pathophysiology of shock”), high concentrations of cytokines in plasma are also associated with a poor outcome (213). Although the levels of these mediators are a direct reflection of the inflammatory process, long laboratory turnaround times make them unsuitable for prognostic evaluation in daily practice.

During the first few hours, patients should be monitored closely because shock may develop after the start of antibiotic treatment (236). It should be borne in mind that monitoring of the systolic blood pressure in children is insufficient to trace the development of shock. Better indicators are low diastolic blood pressure, delayed capillary refill, cold extremities, and tachycardia. Nothing surpasses good clinical surveillance supported by frequent laboratory monitoring. For instance, the progression of DIC can be monitored easily by observing an increase in the number and size of skin hemorrhages and a decrease in the platelet count (492).

THERAPY

In spite of the increasing capabilities of ICUs, survival of patients with invasive meningococcal disease has hardly improved during the last few decades (21, 207). The speed and severity of clinical deterioration in patients with FMS often mandates maximal intensive therapy. Due to the lack of good clinical trials, which for a variety of reasons probably never will be carried out, much of this therapy is controversial. General agreement exists only on two aspects: therapy should never be delayed by diagnostic procedures, and antibiotics are the cornerstone of treatment. However, treatment of shock and the use of glucocorticoids, fresh-frozen plasma, plasma exchange, and other immunomodulating or adjuvant therapies all are subject to debate (65, 222, 255, 259, 313, 361, 430).

Based on good clinical practice and insights into the pathophysiology of the disease, any therapeutic regimen should aim at least to provide (i) early recognition, (ii) prompt start of parenteral antibiotic therapy, and (iii) appropriate and frequently repeated prognostic evaluations. In patients with poor prognostic signs or (imminent) shock, the therapy should be extended to include immediate fluid resuscitation, prompt start of mechanical ventilation, and transfer to an adequately equipped ICU.

Antibiotic Treatment

Antibiotics are the cornerstone of treatment. Serum therapy with serum from immunized horses, introduced at the beginning of this century by Jochmann in Germany and Flexner in the United States, has reduced mortality from nearly 100 to 30% (145, 241). Since their introduction in 1937, sulfonamides decreased mortality to 10% (423). In the 1950s and 1960s, sulfonamide resistance necessitated a switch to penicillin or chloramphenicol. Since the 1980s, decreased penicillin susceptibility (MIC, >0.25 mg/liter) has been reported in several countries (Spain, Greece, Switzerland, Romania, France, Belgium, United Kingdom, Malawi, South Africa, Canada, and the United States (235, 501; P. Botha, Letter, Lancet i:54, 1988; P. Bray, F. Lomppez, M. Guibourdenche, and J. Y. Riou, Letter, Press Med. 24:1910, 1995; G. Riley, S. Brown, and C. Krishnan, Letter, N. Engl. J. Med. 324:997, 1991; A. Round and W. Hamilton, Letter, Lancet i:702, 1988; E. M. Sutcliffe, D. M. Jones, S. El-Sheikh, and A. Percival, Letter, Lancet i:657–658, 1988). This decreased sensitivity is caused by a reduced affinity to penicillin binding protein type 2 (403). Occasionally, penicillin resistance due to plasmid-related β-lactamase production occurs (122). Chloramphenicol resistance has also been reported (155). For patients infected with penicillin-resistant strains, broad-spectrum cephalosporins (e.g., ceftriaxone) are recommended.

Antibiotic therapy should be started as early as possible. Early antibiotic administration does not hinder microbiological diagnosis when a skin biopsy specimen or PCR is used (73). The concern that early antibiotic administration aggravates the clinical condition by causing (β-lactam) antibiotic-induced endotoxin release (30, 230, 370) has never been confirmed clinically (54, 158, 161, 195, 369). In contrast, postponement of antibiotic therapy will result in an increase of bacterial biomass and a more harmful inflammatory response (161). When contacts of patients with meningococcal disease receive parenteral antibiotics at the time they develop fever, no disease develops (22, 161, 225; R. A. Wall, M. Hasson-King, H. Thomas, and B. M. Greenwood, Letter, Lancet i:624, 1986). When antibiotic therapy is started later in the course of the disease, i.e., when ischemic lesions have progressed, more bacteria can escape the effect of antibiotics, since meningococci remain viable in the nonperfused center of these lesions for up to 13 h after the start of antibiotic therapy (499). Sometimes the early administration of antibiotics is disputed because the clinical benefit has not been demonstrated in clinical prospective or retrospective studies. However, since the current evidence about the beneficial effects of antibiotics seems convincing (75, 162, 456, 464; K. Cartwright, J. Strang, S. Gossain, and N. Begg, Letter, Br. Med. J. 305:774, 1992), prospective studies are considered unethical. In addition, most retrospective studies will fail to show an effect of early antibiotic therapy because the
individual course of the disease is highly variable and the study population will be formed by a case mix of patients with a fulminant course (FMS) and patients with an insidious course (meningitis) (257).

Based on these considerations and the intuitive assumption that treatment will be more effective when it is started before damage has occurred (373), in several countries guidelines are promulgated to allow the referring practitioner to start parenteral antibiotic therapy (28; D. Isaacs and P. McIntyre, Letter, Med. J. Aust. 168:195, 1998). Unfortunately, compliance with these guidelines is limited due to a lack of clinical alertness (343, 536, 542; D. Irwin, J. M. Miller, and S. J. Cornell, Letter, Br. Med. J. 312:1538, 1996). A more serious lack of vigilance may occur in the hospital, when diagnostic procedures such as a lumbar tap in FMS patients or CT scanning in meningitis patients delay the start of antibiotic therapy (373, 463, 536, 540).

**Treatment of Shock**

Shock treatment requires cannulation of a large blood vessel. However, this procedure can be troublesome in hypotensive children with coagulopathy, and fatal bleeding may occur when the vessel is ruptured (494). Therefore, it is highly recommended to puncture a compressible vessel, e.g., the femoral vein. When this procedure fails, prompt surgical section is recommended. In emergency situations, fluid can be infused via an intravenous needle (221).

Imperative to the management of shock is early fluid resuscitation and the immediate start of mechanical ventilation. Fluid resuscitation in patients with FMS should be done stepwise with steps of 20 ml/kg. Generally, up to 60 ml/kg in the first 1 h and 120 ml/kg in the following 4 to 6 h are required (70). Sometimes 200 ml/kg during the first 24 h is necessary. The presence of concomitant meningitis does not justify limited fluid therapy (367, 434; W. T. Conner and J. A. Mincielli, Letter, Lancet i:967–969, 1980). Fresh-frozen plasma (FFP) is the fluid of choice (see also “Treatment of diffuse intravascular coagulation” and “Plasma or whole-blood exchange” below). Although it has been suggested that FFP aggravates shock by increasing complement-mediated bacteriolysis in patients with a terminal complement deficiency (284), this risk is considered minimal, since patients with these deficiencies rarely, if ever, present with shock (112, 397).

In addition to the extensive capillary leakage, the early stage of FMS is characterized by severe cardiac depression (45, 314). Consequently, pulmonary congestion may develop early, and this limits the amount of fluid that can be administered. In general, isotropic and vasopressor support is needed from an early stage (222, 255, 259, 309). Dobutamine is preferred for its modulating effect of blocking the extrinsic or intrinsic pathways of coagulation has been evaluated in E. coli-infused baboons. Monoclonal antibodies against TF attenuated shock (166, 203, 228, 229, 406, 425). However, since the healing of ischemic lesions may be surprisingly good in children, conservative treatment should be continued for as long as possible (203, 228). There are no controlled data on the value of decompressive fasciotomy, but in general the results have been disappointing (127, 228).

**Treatment of DIC**

The only successful anti-DIC therapy is antishock therapy. However, endovascular thrombosis, ischemia, and imminent autoamputation may lead to additional treatment. For this purpose, a wide variety of strategies have been suggested. Heparin has been used for several years (100, 437). Although some studies suggest that it leads to less severe distal necrosis, no effect on survival was shown in the few limited trials that have been conducted (159, 198, 270, 299).

When extensive skin or peripheral limb necrosis has progressed, plastic surgery or amputation may be needed (165, 203, 228, 229, 406, 425). However, since the healing of ischemic lesions may be surprisingly good in children, conservative treatment should be continued for as long as possible (203, 228). There are no controlled data on the value of decompressive fasciotomy, but in general the results have been disappointing (127, 228).

New insights into the molecular pathophysiology of DIC may open the way to novel therapies. Thus far, most of these therapies have been tested only in experimental animals, with only a few having been tried in various types of human sepsis or FMS.

The modulating effect of blocking the extrinsic or intrinsic pathways of coagulation has been evaluated in E. coli-infused baboons. Monoclonal antibodies against TF attenuated shock and coagulopathy, whereas monoclonal antibodies against FXIa abrogated only shock (258, 358, 472). No human studies have been reported.

Nonspecific inhibition of serine proteases, the key enzymes in the activation of the contact, complement, kallikrein-kinin, and fibrinolytic systems, was tried in the 1960s with aprotinin (389). Recently, more sophisticated therapies have been reported. One of them involves replenishment of the coagulation inhibitor protein C currently being explored in a phase III trial (166, 387, 390, 391, 437, 471). Stimulation of fibrinolytic activity by streptokinase or TPA has also been reported, but due to...
the high PAI-1 levels the effects are limited and the risk for bleeding complications is not negligible (4, 269, 552; S. Nadel, C. De Munter, J. Britto, P. Habibi, and M. Levin, Letter, Crit. Care Med. 26:971–972; 1998; M. Peters and S. Kerr, Letter, Crit. Care Med. 26:972–973, 1998; W. Zenz, Z. Bodó, G. Zobel, S. Fanconi, and A. Rettenbacher, Letter, Crit. Care Med. 26:969–971, 1998). Extensive zymogen activation can also be modulated by replenishment of serine protease inhibitors (serpins) such as AT-III or C1-INH. AT-III, which inhibits thrombin, FXa, FIIa, FVIIa, and the FXIIa, seems to be promising in the treatment of sepsis of various etiologies (132) and has been used incidentally in FMS (147, 387; S. Nadel, C. De Munter, J. Britto, P. Habibi, and M. Levin, Letter, Crit. Care Med. 26:971–972, 1998; M. Peters and S. Kerr, Letter, Crit. Care Med. 26:972–973, 1998). C1-INH has been tried out in a human sepsis-like syndrome but not in FMS (190). Based on its potent regulating activity of contact, complement, and kallikrein-kinin system activation, its application seems promising (209). Transfusion of platelets is contraindicated because it increases platelet-derived PAI-1 concentrations and aggravates peripheral ischemia and necrosis (52).

So far, none of the above-mentioned single therapies has been shown to be the “magic bullet” (127). In view of the myriad interactions of mediator activation, this may not be surprising. For the time being, FFP, containing various serpins and anticoagulant factors in physiologically balanced amounts, may be the best alternative for fluid resuscitation as well as immunomodulation.

### Immunomodulating Therapies

In experimental models involving infusion of gram-negative bacteria or endotoxin, several antiendotoxin and anticytokine strategies were shown to be protective. Since the pattern of cytokine activation in these models mimics that of FMS (516), it was expected that these strategies would be protective in patients with FMS (328, 508, 534). However, after euphoric preliminary anecdotal reports (196; S. A. Syed, R. H. Taylor, P. M. Crean, and R. J. Stewart, Letter, Lancet 339:496, 1992), controlled trials with human E. coli J5 antibodies and the humanized anti-CD4 antibody HA-1A (Centoxin) failed to show protection (114, 233). To date, the negative results of humanized anti-lipid A IgM antibody HA-1A (Centoxin) failed controlled trials with human E. coli immunomodulation. May be the best alternative for fluid resuscitation as well as anticoagulant factors in physiologically balanced amounts, surprising. For the time being, FFP, containing various serpins and anticoagulant factors in physiologically balanced amounts, may be the best alternative for fluid resuscitation as well as immunomodulation.

### Hemofiltration


However, the rationale of the technique should be questioned (488). It is a misconception that detection of TNF or IL-1 in the ultrafiltrate is compatible with a significant removal of these cytokines (29). Significant removal by any procedure will occur only when the clearance achieved by this procedure outweighs the endogenous clearance. Recently, we estimated that for patients with FMS the endogenous clearance of TNF and IL-1 is at least 30 ml/kg/h (487). Since the maximal clearance that can be achieved by HF is equal to the ultrafiltration rate (approximately 10 to 20 ml/kg/min), HF will not be able to contribute substantially to the removal of TNF or IL-1.

### Plasma or Whole-Blood Exchange

Exchange transfusions have been used for several years in the treatment of neonatal sepsis (482). In 1979, Scharfman et al. described the first plasmapheresis in meningococcal sepsis (W. B. Scharfman, J. R. Tillotson, E. G. Taft, and E. Wright, Letter, N. Engl. J. Med. 300:1277–1278, 1979). Although plasmapheresis appeared to be detrimental in a later trial with dogs with E. coli sepsis (330), at least 16 clinical case reports or clinical series have suggested beneficial effects of plasma exchange or whole-blood exchange with or without leukapheresis (35, 59, 67, 91, 125, 157, 158, 206, 237, 267, 313, 341, 416, 494; M. A. Lewis, Letter, Lancet 347:612–613, 1996; R. G. J. Westendorp, A. Brand, J. Haaren, V. W. M. van Hinsbergh, J. Thompson, R. van Furth, and E. A. Meinders, Letter, Am. J. Med. 92:577–578, 1992). However, since good clinical trials are lacking, the technique is still controversial (361).

Measuring the course of TNF in plasma before and during exchange sessions showed that the natural decrease in the level of TNF in plasma is accelerated during the exchange procedure (158, 487). However, because the exchange sessions are performed intermittently (59, 158, 494), the overall effect of the procedure on the decline in the level of TNF in the first 24 h is limited (487). The effect of exchange techniques on the concentration in plasma of mediators that have a lower endogenous clearance, such as C-reactive protein and the soluble TNF, IL-1, and IL-6 receptors, is clearer (154, 487, 489, 498), but to date it is unresolved whether this effect has any clinical significance.

It should be noted that plasma or whole-blood exchange not only removes plasma but also replenishes various immunomodulating compounds such as the serpins AT-III and C1-INH and the anticoagulant factors protein C and protein S (443). Since the amounts of these compounds infused during the exchange procedures approximate the quantities used in studies with one of the single products (387, 437), it may well be that the beneficial effect of plasma exchange is explained by the infusion of these large amounts of immunomodulating compounds. Because of the failure of immunomodulating strategies with one single product, plasma exchange or whole-blood exchange may be more than a “heroic action in desperately ill patients” (68). Definitely, only comparative randomized trials will be able to determine the true benefits.
**Glucocorticoid Treatment**

The use of glucocorticoids in the treatment of FMS is controversial. Until the early 1980s, it was generally accepted that glucocorticoids decreased early mortality risk in meningococcal meningitis (441). However, more recent studies have suggested that glucocorticoids may contribute to adrenal insufficiency in some patients, particularly those with FMS.

In FMS, adrenal insufficiency has been reported in up to 30% of patients (290, 548), and individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333). Although preterminal cortisol levels do not correlate with mortality (290, 548), individual patients may indeed suffer from adrenal insufficiency (8, 39, 66, 156, 201, 307, 333).

A Synacthen test performed on day 3 in patients with extensive DIC and shock at the ICU of the Nijmegen University Hospital revealed adrenal insufficiency in 3 of the 23 patients (cortisol increase, <0.10 μmol/liter after 250 μg of Synacthen) and an insufficient response in 4 other patients (cortisol increase, <0.20 μmol/liter). Given these facts, glucocorticoids belong to the standard treatment protocol of FMS in this center. However, in view of its side effects, its use remains debated.

**Treatment of Meningitis**

In the absence of imminent cerebral herniation or shock, treatment of meningococcal meningitis is relatively simple and demands only parenteral antibiotics and close monitoring. Fluid restriction is not indicated (367, 434, 468, 481).

The primary goal of therapy is to achieve a rapid bactericidal effect in the CSF (373). Diagnostic procedures such as a CT scan should never delay the start of antibiotic administration (128, 463). Some investigators have suggested that antibiotics exacerbate meningeal inflammation by stimulating endotoxin release (11, 324), and have therefore suggested postponing antibiotic treatment until after dexamethasone was given (405). However, these recommendations are dangerous, since proliferating bacteria shed more endotoxin than those exposed to antibiotics and delay in sterilization of CSF worsens the prognosis (153, 273).

Glucocorticoids, in a recommended dexamethasone dose of four administrations of 0.15 mg/kg/day for 3 days, mitigate cerebral inflammation and, according to some studies, reduce the risk of neurological sequelae in Haemophilus influenza meningitis (372, 523). Since a beneficial effect in other types of meningitis has not been demonstrated, the use of this therapy in meningococcal infections is controversial (373, 405). Other immunomodulating therapies have not yet been tried in human bacterial meningitis.

Lumbar puncture risks brain stem coning and is therefore contraindicated when signs of imminent cerebral herniation are present (382, 544; T. Stephenson, Letter, Br. Med. J. 316: 1015, 1998; A. P. Winrow, Letter, Br. Med. J. 316:1015, 1998). These patients should receive antibiotics and ICU treatment immediately (mechanical ventilation, eventually mannitol or high-dose barbiturates). This treatment should not be delayed by CT scanning or other diagnostic procedures (128, 373, 463).

In general, performance of a second lumbar puncture or CT scan during recovery is not indicated. Meningococcal meningitis responds to appropriate antibiotics, and cerebral abscesses have never been observed.

**PRIMARY PREVENTION**

Invasive disease occurs only in patients devoid of specific bactericidal or opsonizing antibodies. Therefore, the best way to prevent disease is to induce these antibodies by vaccination. Ideally, vaccination should not influence naso-oropharyngeal colonization, the natural reservoir of meningococci, since selection pressure may lead to further immunogenic variability of meningococci.

In the 1960s, polysaccharide vaccines based on group A and C capsule were developed (177). At present, a quadrivalent vaccine containing serogroups A, C, W-135, and Y is available (286). These unconjugated polysaccharide vaccines confer protection to persons older than 2 years even when they are complement deficient (411). Vaccination has been highly effective in the control of community outbreaks and epidemics in military centers (285, 304, 396). Similarly, these polysaccharide vaccines are able to control large epidemics in African countries in the meningitis belt, provided that surveillance is adequate and the vaccination is started before the epidemic threshold is passed (505). Vaccination does not reduce the transfer of bacteria to nonvaccinated persons, and carrier status is unaffected (304, 316).

Nevertheless, the value of unconjugated polysaccharide vaccines is limited because these “thymus-independent” vaccines do not induce immunological memory and the response in children younger than 2 years is poor (84, 348). Induction of immunological memory and a higher efficacy in infants can be realized by conjugating the polysaccharide vaccine to a protein (150, 181, 364). The value of these recently developed conjugated vaccines in mass vaccination is currently under investigation.

The major drawback of the presently available vaccines in Western European countries is the absence of activity against group B meningococci. Since group B polysaccharide is a 200-residue α(2–8) homopolymer of N-acetylneuraminic acid (poly[2-8NeuNAc]) that mimics the human neuronal cell adhesion molecule (143), the use of group B capsule in a vaccine risks the induction of autoimmunity. Since the antibody response to the group B capsule is limited after natural infections, group B capsular polysaccharide is a poor candidate for vaccine development (187). A novel approach is to use a conjugated chemically modified group B capsule, where the N-acetyl group has been replaced by the N-propionyl group (240). Alternative and promising candidates are the surface-exposed OMPs class 1 (PorA) and class 2 (PorB) or LOS (121, 364, 506). Large-scale trials with some of these OMP vaccines in Chile, Cuba, Norway, and Brazil yielded different success rates (37, 110, 311, 431, 554). A recently conducted phase II trial in the United Kingdom and the Netherlands with a Dutch hexavalent outer membrane vesicle vaccine derived from two recombinant multivalent OMP strains and based on six class 1 OMPs present in 80% of the group B isolates in the United Kingdom and The Netherlands (485) gave promising results (74, 109, 214).

Administration of meningococcal (group B) vaccine intranasally induces effective bactericidal antibody titers (197). However, since the concomitant induction of secretory antibodies may influence the natural reservoir of meningococci, which may lead to higher immunogenic variability, further epidemiological research is needed before this technique can be introduced.

**SECONDARY PROPHYLAXIS**

Disease can be prevented by the eradication of the carrier status in subjects likely to harbor virulent meningococci, e.g., housemates of an index patient (422).
Household members and roommates of an index patient have a 1,000-fold-higher chance of acquiring invasive disease than do members of the general population; for pre-primary school contacts, the risk is increased 50-fold (96, 120, 308, 339; R. A. Wall, M. Hasson-King, H. Thomas, and B. M. Greenwood, Letter, Lancet ii:624, 1986). One reason for this increase may be that the conditions needed for invasive disease, in particular the genetic constellation and the occurrence of precedent viral infections, are shared among household members. Since this is not the case for hospital or laboratory personnel, hospital-acquired secondary cases are rare (10, 344, 384, 395; G. Holdsworth, et al., Letter, Lancet 348:1443, 1996).

Chemo prophylaxis for household, day care, and kissing contacts and for medical personnel experiencing intensive contact with oral secretions is recommended by the health authorities of the United States and several European countries. Rifampin is the drug of choice; ciprofloxacin, ofloxacin, minocycline (not in children), and ceftriaxone are good alternatives (167, 243, 371, 420). To prevent reentry of the pathogenic strain into the household after discharge of a patient treated with penicillin, amoxicillin, or chloramphenicol, drugs that do not sterilize the nasopharyngeal mucosa (1), additional prophylaxis before discharge has been suggested (308). However, detailed studies found pathogenic meningococci in only a very small percentage (ca. 1%) of patients after discharge, and therefore the efficacy of sterilizing the naso-oropharynx before discharge is controversial (7, 528).

Chemo prophylaxis may fail because it is given too late or given to the wrong person or because of noncompliance (96, 146, 243, 308). Rifampin resistance, fortunately rare, is another cause of failure (96, 98, 418; P. Yagupsky, S. Ashkerazi, and C. Block, Letter, Lancet 341:1152–1153, 1993). The effect of chemoprophylaxis is further limited because it does not prevent reintroduction of the pathogenic strain from a carrier outside the group, and therefore late secondary cases still occur (457).

Based on the observation that approximately half of the secondary cases in families develop within 24 h in children younger than 15 years, the Norwegian health authorities advise treating these possible coprimary cases with phenoxymethyl penicillin for 1 week (161, 225, 265). Although this strategy has dramatically reduced the number of coprimary fatalities in families, no controlled studies are available and the strategy is debated in other countries (D. M. Jones, Letter, Br. Med. J. 312:1537, 1996; A. Pollard, R. Booy, S. Nadel, and M. Levin, Letter, Br. Med. J. 312:1536, 1996; T. Stokes, R. Shukla, and P. Monk, Letter, Br. Med. J. 312:1536–1537, 1996). One of the concerns is the development of penicillin resistance.

**EPILOGUE**

Because in many cases vaccination is impossible and secondary chemoprophylaxis is of limited value, early diagnosis and prompt appropriate treatment remain the only ways of reducing morbidity and mortality. This requires not only medical acumen and expertise but also permanent vigilance by a well-informed public (179, 180, 388). Unfortunately, the latter is not the case. Media publicity often misinforms and misdirects vigilance by overemphasizing features such as headache, nausea, and stiff neck while neglecting the early and characteristic skin lesions (474). Even in 2000, the old thinking that meningococcal disease consists primarily of meningitis lives firmly in the minds of many people including physicians (345; A. Corke, R. Anderson, M. Darda, J. Bhachu, V. Franklin, S. Chen, J. Taylor, N. Choud bury, and T. Christmas, Letter, Br. Med. J. 312:311–312, 1996). With respect to this, little has changed since the time of Herrick, who began his article in 1919 with the following (217):

The meningeal picture resulting from meningococcal infection has so fixed the attention of clinicians and pathologists that the possibilities of extrameningeal infection have had scant notice. This has resulted in a general failure to recognize the fundamental nature of the disease as a meningococcus septicemia, which has in turn had important consequences in the field of diagnosis and treatment.

**ACKNOWLEDGMENTS**

We acknowledge the staff of the Intensive Care Unit of the University Hospital Nijmegen, Nijmegen, The Netherlands (head, S. J. H. van Leeuwen), where the clinical part of this study was conducted.

**REFERENCES**


25. Reference deleted.
27. Reference deleted.
PATHOGENESIS AND MANAGEMENT OF MENINGOCOCAL DISEASE

159


Reference deleted.


Reference deleted.


Reference deleted.


Reference deleted.


Reference deleted.


Reference deleted.


Reference deleted.


Reference deleted.
